Hospitals have adopted a take-no-prisoners approach in the fight with Big Pharma over the 340B drug discount program. Can this strategy hold as Congress, oversight agencies, the courts and the Trump administration ratchet up scrutiny of the program?
HHS received over 3,000 comments on the Trump administration's Blueprint to Lower Drug Prices, which was released in May. Hospitals, health insurers and drugmakers had plenty to say on how to address soaring drug prices
Between 2010 and 2017, more than 19 million people moved from the ranks of the uninsured to insured. With the 2019 open-enrollment season fast approaching, here's a look at some key demographic data.
Egypt's national hospitals now offer a mandatory musical interlude each morning at 8: the national anthem, “My Homeland,” plays on intercoms. After that comes the Hippocratic oath.
The CMS sent a rule to the White House for review that may resume risk-adjustment payments to insurers. Patient advocates have claimed the agency was trying to sabotage the insurance exchanges by eliminating billions in payments.
HHS is taking steps to remove legal protections for drug rebates that favor pharmacy benefit managers. It's unclear whether the changes will actually lead to lower drug prices, experts say.
House Democrats launched a Medicare for All caucus and its founder says some hospital leaders have been cautiously supportive behind closed doors.
HHS Secretary Alex Azar has chosen Adam Boehler to help oversee efforts to develop value-based care initiatives at the agency.
The Senate Health, Education, Labor and Pensions Committee held its second hearing on healthcare spending Tuesday, with lawmakers and witnesses trying to drill down on big questions that could lead to concrete health policy.
A federal district judge rejected Planned Parenthood and the ACLU's bid to freeze the Trump administration's new funding criteria for the Title X family planning program, leaving the existing network of grantees in limbo.
The Trump administration's effort to reduce drug prices should not include altering or cutting the 340B program as it won't lead to lower drug costs, hospitals are telling HHS.
HHS Secretary Alex Azar in a meeting with several key House GOP lawmakers suggested standardizing the discount for 340B drugs at 20% of list price, far below the current 40% to 60% discount.